X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multiple sclerosis (246) 246
index medicus (208) 208
placebo-controlled phase-3 (200) 200
humans (187) 187
oral bg-12 (167) 167
clinical neurology (154) 154
dimethyl fumarate (122) 122
double-blind (106) 106
neurosciences (94) 94
immunosuppressive agents - therapeutic use (79) 79
female (78) 78
male (78) 78
multiple sclerosis, relapsing-remitting - drug therapy (75) 75
pharmacology & pharmacy (70) 70
multiple sclerosis - drug therapy (69) 69
neurology (69) 69
placebo-controlled trial (64) 64
adult (63) 63
drug therapy (58) 58
treatment outcome (58) 58
fingolimod (54) 54
administration, oral (52) 52
patients (51) 51
safety (51) 51
interferon (49) 49
middle aged (49) 49
multiple-sclerosis (49) 49
care and treatment (46) 46
oral fingolimod (46) 46
clinical trials (45) 45
glatiramer acetate (45) 45
bg-12 (44) 44
efficacy (44) 44
medicine & public health (44) 44
research (41) 41
animals (40) 40
dimethyl fumarate - therapeutic use (40) 40
teriflunomide (39) 39
immunosuppressive agents - administration & dosage (36) 36
progressive multifocal leukoencephalopathy (36) 36
oxidative stress (35) 35
review (35) 35
acid esters (34) 34
analysis (34) 34
experimental autoimmune encephalomyelitis (34) 34
magnetic resonance imaging (34) 34
immunology (33) 33
immunosuppressive agents - adverse effects (33) 33
inflammation (33) 33
multicenter (33) 33
natalizumab (33) 33
oral teriflunomide (33) 33
disease progression (31) 31
disease-modifying therapies (31) 31
therapy (30) 30
controlled phase-3 (29) 29
fumarates - therapeutic use (29) 29
interferon beta-1a (29) 29
disability (28) 28
lymphocytes (26) 26
medicine, general & internal (26) 26
medicine (25) 25
psoriasis (25) 25
studies (25) 25
activation (24) 24
fumarates - administration & dosage (24) 24
interferon-beta (24) 24
psychiatry (24) 24
alemtuzumab (23) 23
internal medicine (23) 23
nuclear magnetic resonance--nmr (23) 23
trial (23) 23
disease (22) 22
fumaric-acid esters (22) 22
immunologic factors - therapeutic use (21) 21
neuroprotection (21) 21
fumaric acid (20) 20
central-nervous-system (19) 19
dimethyl (19) 19
fumarates - pharmacology (19) 19
immunosuppressive agents - pharmacology (19) 19
usage (19) 19
drugs (18) 18
fumarates - adverse effects (18) 18
intramuscular interferon (18) 18
medical research (18) 18
relapsing-remitting multiple sclerosis (18) 18
young adult (18) 18
clinical trials as topic (17) 17
double-blind method (17) 17
article (16) 16
crotonates - therapeutic use (16) 16
cytokines (16) 16
diagnosis (16) 16
dimethyl fumarate - administration & dosage (16) 16
disease-modifying therapy (16) 16
esters (16) 16
health aspects (16) 16
lymphocytes t (16) 16
natural-history (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2012, Volume 367, Issue 12, pp. 1098 - 1107
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2012, Volume 367, Issue 12, pp. 1087 - 1097
Journal Article
Journal Article
Neurology, ISSN 0028-3878, 04/2019, Volume 92, Issue 15, pp. 696 - 697
Journal Article
NEUROLOGY, ISSN 0028-3878, 04/2018, Volume 90, Issue 17, pp. 789 - 800
Objective To review evidence on starting, switching, and stopping disease-modifying therapies (DMTs) for multiple sclerosis (MS) in clinically isolated... 
CONTROLLED PHASE-3 | MULTICENTER | INTRAMUSCULAR INTERFERON | DOUBLE-BLIND | BG-12 | PLACEBO-CONTROLLED TRIAL | METHYLPREDNISOLONE | FINGOLIMOD | ORAL TERIFLUNOMIDE | INTERFERON BETA-1A | CLINICAL NEUROLOGY
Journal Article
LANCET NEUROLOGY, ISSN 1474-4422, 07/2016, Volume 15, Issue 8, pp. 790 - 791
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 2013, Volume 369, Issue 11, pp. 1081 - 1082
Journal Article
Frontiers in Neurology, ISSN 1664-2295, 01/2018, Volume 9, p. 5
Dimethyl fumarate (DMF) is an effective treatment option for relapsing-remitting multiple sclerosis (MS), but its therapeutic mechanism of action has not been... 
Neuroprotection | BG-12 | Inflammation | Lymphopenia | Antioxidant | antioxidant | OXIDATIVE STRESS | PLACEBO-CONTROLLED PHASE-3 | MRI MEASURES | NEUROSCIENCES | ORAL BG-12 | CLINICAL NEUROLOGY | IN-VITRO | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | inflammation | neuroprotection | DISEASE-MODIFYING THERAPIES | MEMORY T-CELLS | NF-KAPPA-B | lymphopenia | ACID ESTERS | Drug therapy | Multiple sclerosis | Research
Journal Article